Opinion|Videos|January 3, 2025
Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?
Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the issue of slot availability for chimeric antigen receptor (CAR) T-cell therapy, along with the waiting list, fit into the ongoing challenges faced at the institutional level?
- Dr Abdallah to ask Dr Mushtaq: If you choose to use CAR T-cell therapy in earlier lines of therapy, what might you do next and why?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5